Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August

Prices Well Below $100/vial

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Coins, money and COVID-19 on scale. Concepts of economics against coronavirus. Balancing and managing losses. 3D render
Hetero, Cipla Hit Market With Generic Remdesivir • Source: Shutterstock

There has been a flurry of activity around investigational COVID-19 treatments in India over the past weekend.

While Glenmark Pharmaceuticals Ltd. became the first Indian firm to get the go-ahead for its version of the oral...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia